Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Metallothioneins (MTs) are crucial proteins involved in cellular processes including ion binding, differentiation, proliferation, and apoptosis, all of which can contribute to cancer development.
• Limited data exists regarding the expression patterns of MTs in various thyroid lesions, particularly in distinguishing benign from malignant conditions.

Purpose of the Study:

• To investigate the mRNA expression levels of multiple functional MT isoforms in benign thyroid lesions (nodular goiters and follicular adenomas) and malignant thyroid lesions (papillary thyroid carcinoma).
• To determine if MT expression patterns can serve as potential biomarkers for differentiating benign and malignant thyroid tumors.

Main Methods:

• Quantitative analysis of mRNA expression for MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1X, MT2A, and MT4 genes.
• Samples included 17 nodular goiters (NG), 12 follicular adenomas (FA), and 26 papillary thyroid carcinomas (PTC).
• Statistical analysis using one-way ANOVA and post hoc tests to compare expression levels between groups.

Main Results:

• Significant differences in mRNA expression were observed for MT1A, MT1E, MT1F, MT1G, MT1X, and MT2A across the analyzed thyroid samples.
• Papillary thyroid carcinomas (PTC) showed significantly lower mRNA expression of multiple MT isoforms (MT1A, MT1E, MT1F, MT1G, MT1X, MT2A) compared to nodular goiters (NG).
• Follicular adenomas (FA) also exhibited significantly lower expression of MT1F and MT1G compared to nodular goiters (NG).

Conclusions:

• The differential expression of functional MT isoforms in thyroid lesions suggests their involvement in the process of thyroid carcinogenesis.
• Down-regulation of specific MT isoforms in malignant thyroid tumors may indicate their potential utility as diagnostic markers for distinguishing between benign and malignant thyroid lesions.